Pioneering Precision Medicine: A Hybrid Future for CDx

In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine.

Attendee will:

• Discover SOPHiA GENETICS’ and Myriad Genetics’ first-of-its-kind CDx partnership model to unlock scale, regulatory compliance, and access to precision diagnostics and therapies
• Gain insights into what a co-development strategy for CTA and CDx looks like in practice and how it enables simultaneous development and deployment at a central lab
• Understand how Pharma-Diagnostics collaborations can support late-stage clinical development through commercialisation